## **Core Concept**
The question tests the understanding of pharmacological properties of non-depolarizing muscle relaxants, specifically their duration of action and metabolism. Non-depolarizing muscle relaxants are competitive antagonists at the nicotinic acetylcholine receptor, and their recovery can be influenced by their elimination and metabolism.

## **Why the Correct Answer is Right**
The correct answer, **Sugammadex**, is a selective relaxant binding agent (SRBA) that encapsulates certain non-depolarizing neuromuscular blocking agents (NMBAs), like rocuronium and vecuronium, effectively reversing their action. However, among the traditional non-depolarizing muscle relaxants, **Atracurium** is known for its unique metabolism through Hofmann elimination, a chemical process independent of liver or kidney function. This allows atracurium to undergo spontaneous degradation in plasma, which can lead to recovery from its effects without the need for reversal agents.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Mivacuronium is metabolized by plasma cholinesterase, and its short duration of action could allow for spontaneous recovery, but it's not as commonly associated with this property in the context of not needing reversal as much as atracurium.
- **Option B:** Vecuronium primarily undergoes hepatic elimination and biliary excretion, and while it has an intermediate duration of action, spontaneous recovery without reversal is less likely compared to atracurium.
- **Option D:** Pancuronium has a long duration of action and is primarily excreted by the kidneys, making spontaneous recovery without reversal unlikely.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **Atracurium** is unique due to its metabolism via Hofmann elimination, making it a relaxant from which patients can recover spontaneously without reversal, especially in patients with renal or hepatic dysfunction.

## **Correct Answer:** . Atracurium